Pharmaceutical composition of valsartan: β-Cyclodextrin: Physico-chemical characterization and anti-hypertensive evaluation

Molecules

Volumn 15, Issue 6, 2010, Pages 4067-4084

  De Matos Jensen, Carlos Eduardo ^a,b   Dos Santos, Robson Augusto Souza ^a   Denadai, Angelo Márcio Leite ^a   Santos, Cynthia Fernandes Ferreira ^a   Braga, Aline Nardoni Gonçalves ^a   Sinisterra, Ruben Dario ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

Author keywords

Cyclodextrin; Anti hypertensive evaluation; Intrinsic dissolution; ROESY; Valsartan

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLODEXTRIN; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ANIMAL; ARTICLE; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; HYPERTENSION; INFRARED SPECTROSCOPY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT; WISTAR RAT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CYCLODEXTRINS; HYPERTENSION; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MOLECULAR STRUCTURE; RATS; RATS, WISTAR; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TETRAZOLES; VALINE;

EID: 77954283901     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15064067     Document Type: Article

References (40)

1. Ladak, N.; Thompson, J. Drugs acting on the heart: antihypertensive drugs. Anaesth. Intensive Care Med. 2009, 10, 392-395.
2. Mahmud, A.; Feely, J. Low-dose quadruple antihypertensive combination more efficacious than individual agents-a preliminary report. Hypertension 2007, 49, 272-275.
3. Ibrahim, M. M. RAS inhibition in hypertension. J. Human Hypert. 2006, 20, 101-108.
4. Tamargo, J.; Caballero, R.; Gómez, R.; Núñez, L.; Vaquero, M.; Delpón, E. Características farmacológicas de los ARA-II. ¿Son todos iguales? Rev. Esp. Cardiol. Supl. 2006, 6, 10C-24C.
5. Li, H.; Wang, Y.; Jiang, Y.; Tang, Y.; Wang, J.; Zhaob, L., Gua, J. A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. J. Chromatogr. B 2007, 852, 436-442. (Pubitemid 46830149)
6. Brunner, H. R. The new angiotensin II receptor antagonist, irbesartan. Am. J. Hypertens. 1997, 10, 331S-317S.
7. Zusman, R. M. Are there differences among angiotensin receptor blockers? Am. J. Hyperten. 1999 12, 231S-235S.
8. Therapeutic sytems reseearch laboratories, biopharmaceutics classification system. http://www.tsrlinc.com/services/bcs/results.cfm (2010) (accessed 6 March 2010).
9. Uekama, K; Hirayama, F.; Irie, T. Cyclodextrin Drug Carrier Systems. Chem. Rev. 1998, 98, 2045-2076.
10. Loftsson, T. Cyclodextrins and the Biopharmaceutics Classification System of Drugs. J. Incl. Phenom. Macro. Chem. 2002, 44, 63-67.
11. Loftsson, T.; Duchêne, D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 2007, 329, 1-11.
12. Brewster, M. E.; Loftsson, T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliver. Rev. 2007, 59, 645-666.
13. Szejtli, J. Introduction and General Overview of Cyclodextrin Chemistry. Chem. Rev. 1998, 98, 1743-1753.
14. Challa, R.; Ahuja, A.; Ali, J.; Khar, R. K. Cyclodextrins in Drug Delivery: An Updated Review. AAPS Pharm. Sci. Tech. 2005, 6, E329-E357.
15. Martin Del Valle, E. M. Cyclodextrins and their uses: a review. Process Biochem. 2004, 39, 1033-1046.
16. Higuchi, T.; Connors, K. A. Phase solubility techniques. Adv. Anal. Chem. Instrum. 1965, 4, 117-212.
17. Cappello, B.; Di Maio, C.; Lervolino, M.; Miro, A. Improvement of Solubility and Stability of Valsartan by Hydroxypropyl-β-Cyclodextrin. J. Incl. Phenom. Macrocycl. Chem. 2006, 54, 289-294.
18. Karathanos, V. T.; Mourtzinos, I.; Yannakopoulou, K.; Andrikopoulos, N. K. Study of the solubility, antioxidant activity and structure inclusion complex of vanillin with β-cyclodextrin. Food Chem. 2007, 101, 652-658.
19. Loftsson, T.; Hreinsdoóttir, D.; Másson, M. The complexation efficiency. J. Incl. Phenom. Macrocycl. Chem. 2007, 57, 545-552.
20. Jullian, C.; Orosteguis, T.; Pérez-Cruz, F.; Sánchez, P.; Mendizabal, F.; Olea-Azar. C. Complexation of morin with three kinds of cyclodextrin: A thermodynamic and reactivity study. Spectrochim. Acta Part A 2008, 71, 269-275.
21. Giordano, F.; Novak, C.; Moyano, J. R. Thermal analysis of cyclodextrins and their inclusion compounds. Thermochim. Acta 2001, 380, 123-151.
22. Turnbull, W. B.; Daranas, A. H. On the value of c: can low affinity systems be studied by isothermal titration calorimetry? J. Am. Chem. Soc. 2003, 125, 14859-14866.
23. Loftsson, T.; Hreinsdoóttir, D.; Másson, M. The complexation efficiency. J. Incl. Phenom. Macrocycl. Chem. 2007, 57, 545-552.
24. Cepanec, I.; Litvic, M.; Bartolincic, A.; Sporec, A.; Druskovic, V. Process for production of inclusion complexes of valsartan with β-cyclodextrin. WO/2005/056607. 23.06.2005
25. Bettinetti, G.; Novák, C.; Sorrenti, M. Thermal and structural characterization of commercial α-, β-, and δ-cyclodextrins. J. Therm. Anal. Calorim. 2002, 68, 517-529.
26. Orgoványi, J.; Pöppl, L.; Otta, K. H.; Lovas, G. A. Thermoanalytical method for studying the guest content in cyclodextrin inclusion complexes. J. Therm. Anal. Calorim. 2005, 81, 261-266.
27. Winters, C. S.; York, P.; Timmins, P. Solid state examination of a gliclazide:beta-cyclodextrin complex. Eur. J. Pharm. Sci. 1997, 5, 209-214.
28. Pravin, N.; Babasaheb, A.; Neha, D.; Vilasrao, K.; Rajashree, H. Solid state characterization of the inclusion complex of valsartan with methyl β-cyclodextrin. J. Incl. Phenom. Macrocycl. Chem. 2009, 65, 377-383.
29. The United States pharmacopeia, 31st ed.; The United States Pharmacopeial Convention: Rockville, Maryland, MD, USA, 2007; General Chapter Number >1087<.
30. Blagden, N.; De Matas, M.; Gavan, P. T.; York, P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv. Drug Delivery Rev. 2007, 59, 617-630.
31. Al Omari, M. M.; Zughul, M. B.; Davies, J. E. D.; Badwan, A. A. Sildenafil/cyclodextrin complexation: Stability constants, thermodynamics, and guest-host interactions probed by 1H NMR and molecular modeling studies. J. Pharm. Biomed. Anal. 2006, 41, 857-865.
32. Ficarra, R.; Tommasini, S.; Raneri, D.; Calabrò, M. L.; Di Bella, M. R.; Rustichelli, C.; Gamberini, M. C.; Ficarra, P. Study of flavonoids/β-cyclodextrins inclusion complexes by NMR, FT-IR, DSC, X-ray investigation. J. Pharm. Biomed. Anal. 2002, 29, 1005-1014.
33. Sun, D. Z.; Li, L.; Qiu, X. M.; Liu, F.; Yin, B. I. Isothermal titration calorimetry and 1H NMR studies on host-guest interaction of paeonol and two of its isomers with β-cyclodextrin. Int. J. Pharm. 2006, 316, 7-13.
34. Fronza, G.; Mele, A.; Redenti, E.; Ventura, P. 1H NMR and molecular modeling study on the inclusion complex β-cyclodextrin-indomethacin. J. Org. Chem. 1996, 61, 909-914.
35. Bernini, A.; Spiga, O.; Ciutti, A.; Scarselli, M.; Bottoni, G.; Mascagni, P.; Niccolai, N. NMR studies of the inclusion complex between β-cyclodextrin and paroxetine. Eur. J. Pharm. Sci. 2004, 22, 445-450.
36. Lula, I.; Gomes, M. F.; Veloso, D. P.; Noronha, A. L. O.; Duarte, H. A.; Santos, R. S.; Sinisterra, R. D. Spironolactone and its complexes with b-cyclodextrin: modern NMR characterization and structural DFTB-SCC Calculations. J. Incl. Phenom. Macrocycl. Chem. 2006, 56, 293-302.
37. Denadai, A. M. L.; Ianzer, D. Alcântara, A. F. C.; Santoro, M. M.; Santos, C. F. F.; Lula, I. S.; Camargo, A. C. M.; Faljoni-Alario, A.; Santos, R. A. S.; Sinisterra, R. D. Novel pharmaceutical composition of bradykinin potentiating penta peptide with β-cyclodextrin: Physical-chemical characterization and anti-hypertensive evaluation. Int. J. Pharm. 2007, 336, 90-98.
38. Schneider, H. J.; Hacket, F.; Rüdiger, V.; Ikeda, H. NMR studies of cyclodextrins and cyclodextrin complexes. Chem. Rev. 1998, 98, 1755-1785.
39. Werner, M. H. Advanced User's Guide, Brucker. >940712<; Spectrospin A. G.: Fallanden, Switzerland, 1994.
40. Rahman, A. One and Two Dimensional NMR Spectroscopy, 1st ed.; Elsevier: New York, NY, USA, 1989.